Biolegend, 405226, Brilliant Violet 421™ Streptavidin, 100microl

Streptavidin binds to biotin with high affinity. Streptavidin-Brilliant Violet 421™ is useful for detecting biotinylated antibodies. The excitation of Brilliant Violet 421™ by 405 nm laser light induces a fluorescence maximum emission of 421 nm.
100microl
Verified Reactivity: Human, Mouse, Rat, All Species
Formulation: Cat. No. 405225: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.Cat. No. 405226: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: Streptavidin was conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: 405225 is bottled at 0.5 mg/ml. 405226 is bottled at 0.1 mg/ml.(concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling: The solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC, ICFC - Quality tested ICC, IHC-F, IHC-P
Recommended Usage: Each lot of this Streptavidin-Brilliant Violet 421™ is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the Brilliant Violet 421™ conjugation. For immunofluorescent staining, we recommend using Cat. No. 405226 at dilutions ≤ 0.015 µg in 100 µL staining volume per million cells. For applications requiring high concentration of streptavidin reagent such as tetramer labeling, we recommend using Cat. No. 405225. It is recommended that the reagent be titrated for optimal performance for each application. * Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Streptavidin-Brilliant Violet 421™ is useful as a second step reagent for indirect immunofluorescent staining when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-Brilliant Violet 421™ is 340 kD and Streptavidin alone is 52 kD.
Additional Product Notes: View more applications data using this product in immunofluorescence microscopy and labeling tetramers in flow cytometry in our Scientific Poster Library.
Application References(PubMed link indicates BioLegend citation): Kim G, et al. 2013. J. Immunol. 190:1510. PubMed. Giltiay NV, Et al. 2013. J. Immunol. 191:2155. PubMed Sugiyama D, et al. 2013. PNAS. 110:17945. PubMed Scally SW, et al. 2013. J. Exp Med. 210:2569. PubMed Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed Higdon LE, et al. 2014. PNAS. 111:5652. PubMed Friedman RS, et al. 2014. PNAS. 111:9223. PubMed van de Weijer ML, et al. 2014. Nat Commun. 5:3832. PubMed Mise-Omata S, et al. 2014. Int Immunol. PubMed Choo JA, et al. 2014. J Virol. 88:10613. PubMed Xing YL, et al. 2014. J Neurosci. 34:14128. PubMed Luetke-Eversloh M, et al. 2014. PLoS Pathog. 10:1004441. PubMed Poh Cm, et al. 2014. Infect Immun. 82:4854. PubMed Cabrera-Perez J, et al. 2015. J Immunol. 194:1609. PubMed Lucas A, et al. 2015. PLoS One. 10:117160. PubMed Krishnaswamy JK, et al. 2015. PNAS. 112:3056. PubMed Rampuria P, et al. 2015. Int Immunol. 27:253. PubMed
Product Citations: Takizawa F, et al. 2016. J Immunol. 196: 4522 - 4535. PubMed Angkasekwinai P, et al. 2017. PLoS One. 10.1371/journal.pone.0184684. PubMed van Eeden C, et al. 2018. Cell Rep. 25:3123. PubMed Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed Tas JMJ, et al. 2022. Immunity. 55:1856. PubMed Sun P, et al. 2022. iScience. 25:105202. PubMed Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed Vyasamneni R, et al. 2023. Cell Rep Methods. 3:100388. PubMed Kawai H, et al. 2023. JBMR Plus. 7:e10722. PubMed Nihei Y, et al. 2023. Sci Adv. 9:eadd6734. PubMed Marcial-Juárez E, et al. 2023. iScience. 26:106310. PubMed Liu KY, et al. 2023. Environ Health Perspect. 131:37014. PubMed Ramalingam P, et al. 2023. Nat Commun. 14:2018. PubMed Lu T, et al. 2023. J Med Virol. 95:e28730. PubMed Fadzeyeva E, et al. 2023. iScience. 26:106748. PubMed Sigmund EC, et al. 2023. PLoS One. 18:e0285597. PubMed Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed Steines L, et al. 2021. Front Immunol. 12:657894. PubMed García-Alegria E, et al. 2021. STAR Protoc. 2:100367. PubMed Reyes RA, et al. 2021. PLoS One. 16:e0261656. PubMed Combes AJ, et al. 2022. Cell. 185:184. PubMed He T, et al. 2022. Liver Int. 42:1287. PubMed Lee JH, et al. 2022. Cell Rep. 38:110485. PubMed Wolf EW, et al. 2022. Proc Natl Acad Sci U S A. 119:e2201794119. PubMed Tátrai P, et al. 2022. EMBO J. 41:e108739. PubMed Lei X, et al. 2022. J Exp Med. 219: . PubMed Gupta S, et al. 2022. Sci Adv. 8:eabn4886. PubMed Wang Z, et al. 2022. J Exp Med. 219: . PubMed Buckner CM, et al. 2022. Cell. 185:4333. PubMed Ogishi M, et al. 2023. J Exp Med. 220: . PubMed Scharf L, et al. 2023. JCI Insight. 8: . PubMed Touizer E, et al. 2023. iScience. 26:105862. PubMed Weskamm LM, et al. 2022. STAR Protoc. 3:101902. PubMed Bettini E, et al. 2022. STAR Protoc. 3:101840. PubMed Guo Q, et al. 2023. Front Public Health. 10:1067342. PubMed Meyer S, et al. 2023. Cell Rep. 42:111995. PubMed Zhang S, et al. 2023. J Clin Med. 12: . PubMed Yeh CH, et al. 2022. Immunity. 55:272. PubMed Hayashi M, et al. 2017. EBioMedicine. 15:127-136. PubMed Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed Domingues AF, et al. 2020. Elife. 9:e51754. PubMed Parra–Sánchez H, et al. 2019. Viruses. 1.153472222. PubMed Miura M, et al. 2019. Wellcome Open Res. 3:105. PubMed Li H, et al. 2022. Front Immunol. 13:988004. PubMed Chaugule S, et al. 2021. Int J Mol Sci. 22:. PubMed Xing Y, et al. 2014. J Neurosci. 34:14128. PubMed Sei J, et al. 2016. PLoS One. 11: 0152192. PubMed Li H, et al. 2016. J Immunol. 196: 4064 - 4074. PubMed Sage P, et al. 2016. Nat Immunol. 17:1436-1446. PubMed Kato T, et al. 2019. Front Immunol. 10:2021. PubMed Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed Xiong W, et al. 2021. Int J Mol Sci. 22:. PubMed Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed Trivedi S, et al. 2015. Vaccine. 33: 7315-7327. PubMed Sugiyama D, et al. 2013. Proc Natl Acad Sci U S A. 110:17945. PubMed Giltiay N, et al. 2013. J Immunol. 191:2155. PubMed Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed Mitra T, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.035. PubMed Poon MML, et al. 2021. Sci Immunol. 6:eabl9105. PubMed Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed Zhao M, et al. 2019. Cell Rep. 26:652. PubMed Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed Li T, et al. 2022. Int J Infect Dis. 122:874. PubMed Fachi JL, et al. 2020. J Exp Med. 217:00:00. PubMed Im S, et al. 2016. Nature. 537:417-421. PubMed Poh C, et al. 2014. Infect Immun . 82:4854. PubMed Nakagawa T, et al. 2021. Cell Rep. 37:109875. PubMed Gaudette BT, et al. 2021. J Clin Invest. 131:. PubMed Cai D, et al. 2021. Front Mol Biosci. 8:686803. PubMed Koay H, et al. 2016. Nat Immunol. 10.1038/ni.3565. PubMed Lucas A, et al. 2015. PLoS One. 10:117160. PubMed Neumann B, et al. 2019. Cell Stem Cell. 25:473. PubMed Xu L et al. 2017. Immunity. 47(3):538-551 . PubMed Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed Zhang R, et al. 2021. MAbs. 13:1904546. PubMed Krishnaswamy J, et al. 2015. Proc Natl Acad Sci U S A. 112:3056. PubMed Cameron G, et al. 2015. J Immunol. 195: 4604 - 4614. PubMed Rowan A, et al. 2016. PLoS Pathog. 12:e1006030. PubMed Taguchi A, et al. 2017. Cell Stem Cell. 21:730. PubMed Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed Glaros V, et al. 2021. Immunity. 54:2005. PubMed Bähr A, et al. 2016. PLoS One. 11: 0155676. PubMed Xu Z, et al. 2016. Nat Commun. 7:10728. PubMed Liu B, et al. 2015. J Immunol. 194:3583. PubMed Lin C, et al. 2022. Nat Commun. 13:6869. PubMed Tarke A, et al. 2022. Cell. 185:847. PubMed Nosho S, et al. 2020. Int J Mol Sci. 21:00. PubMed Alameh MG, et al. 2021. Immunity. 54:2877. PubMed Cavazzoni CB, et al. 2022. Cell Rep. 38:110399. PubMed Roberts E, et al. 2016. PLoS One. 11:e0168488. PubMed Elayeb R, et al. 2016. Haematologica. 101: 209 - 218. PubMed Cuenca M, et al. 2016. J Immunol. 196: 726 - 737. PubMed Weijer M, et al. 2014. Nat Commun. 5:3832. PubMed Delacher M, et al. 2020. Immunity. 52:295. PubMed Sanjo H, et al. 2015. PLoS One. 10: 0128761. PubMed Ma X, et al. 2020. Immunity. 53:1315. PubMed Hasegawa T, et al. 2020. Sci Rep. 10:13480. PubMed Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed Parra-Sánchez H, et al. 2018. Mol Immunol. 96:1. PubMed Borroto A, et al. 2022. Front Immunol. 13:799919. PubMed Song R, et al. 2022. Front Immunol. 13:1028246. PubMed Yang E, et al. 2016. J Immunol. 197: 934 - 941. PubMed Salzberger W, et al. 2015. PLoS One. 10: 0145324. PubMed Tsuzuki S, et al. 2015. Int Immunol. 10.1093/intimm/dxv058. PubMed Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed Scally S, et al. 2013. J Exp Med. 210:2569. PubMed Blomberg R, et al. 2019. Matrix Biol. 83:60. PubMed Claudepierre M, et al. 2014. J Virol. 88:5242. PubMed Friedman R, et al. 2014. Proc Natl Acad Sci U S A. 111:9223. PubMed Lundell A, et al. 2017. Sci Rep. 7:39904. PubMed Fra-Bido S, et al. 2021. STAR Protocols. 2(3):100499. PubMed Cirelli KM et al. 2019. Cell. 177(5):1153-1171 . PubMed Wen J, et al. 2020. Cell Rep. 31:107566. PubMed Wang Z, et al. 2022. J Exp Med. 219:. PubMed Guelen L, et al. 2022. J Immunother Cancer. 10:. PubMed Dan JM, et al. 2021. Science. :371. PubMed Mise-Omata S, et al. 2014. Int Immunol. 26:607. PubMed Tulyeu J, et al. 2021. Curr Protoc. 1:e283. PubMed Lederer K, et al. 2022. Cell. . PubMed Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed Luetke-Eversloh M, et al. 2014. PLoS Pathog. 10:1004441. PubMed Lang P 2015. Int Immunol. 27:253. PubMed Younis R, et al. 2016. J Immunol. 196: 1419 - 1429. PubMed Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed Zhu L, et al. 2016. J Cell Sci. 129: 4238 - 4251. PubMed An X, et al. 2017. PLoS One.. 10.1371/journal.pone.0181904. PubMed Yoshida H, et al. 2019. Cell. 176:897. PubMed Fries CN, et al. 2021. Sci Rep. 11:14494. PubMed Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed Clement RL, et al. 2019. Nat Immunol. 20:1360. PubMed Kim JM, et al. 2020. Nat Commun. 11:2289. PubMed Silva HM, et al. 2019. J Exp Med. 216:786. PubMed Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed Wells DK, et al. 2020. Cell. 183:818. PubMed Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed Choo J, et al. 2014. J Virol. 88:10613. PubMed Mesin L, et al. 2020. Cell. 180(1):92-106.e11.. PubMed Mahmoudi S, et al. 2019. Nature. 574:553. PubMed Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed Higdon L, et al. 2014. Proc Natl Acad Sci U S A. 111:5652. PubMed Kim G, et al. 2013. J Immunol. 190:1510. PubMed Binnewies M, et al. 2019. Cell. 177:556. PubMed Cho A, et al. 2022. J Exp Med. 219:. PubMed Brunk F, et al. 2021. Eur J Immunol. 51:2651. PubMed Giri T, et al. 2022. Heliyon. 8:e09407. PubMed
Gene ID: NA
UniProt: View information about Biotin on UniProt.org
Regulatory Status: RUO
Other Names: SAv-Brilliant Violet 421™
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.